Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live News

Zydus Lifesciences announced that the USFDA conducted an inspection at the group`s Unit � 2 manufacturing plant at Ankleshwar, Gujarat. The inspection was conducted from 19th to 23rd January, 2026 and concluded with 3 observations. There were no data integrity related observations. The Company will closely work with the USFDA to address the observations expeditiously.Powered by Capital Market - Live News

Zydus Lifesciences has launched the world`s first biosimilar of Nivolumab in India under the brand name Tishtha�, reinforcing the company`s growing capability in advanced biologics and Immuno-Oncology. Tishtha� will be available in 100 mg and 40 mg dosages priced at Rs 28,950 and Rs 13,950 respectively. The prices are approximately 1/4th of the reference drug. This will improve affordability and reduce the overall treatment burden for patients. The two strength portfolio enables oncologists to optimise dosing and minimise wastage - a key driver of treatment economics in immunotherapy. Powered by Capital Market - Live News

Sentynl Therapeutics Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences (Zydus Group), announced that the U.S. Food and Drug Administration has approved ZYCUBO� (copper histidinate) for the treatment of Menkes disease in pediatric patients. This is the first and only treatment approved for Menkes disease, a rare and fatal genetic condition, in the United States. ZYCUBO� is not indicated for the treatment of Occipital Horn Syndrome. Menkes disease is a rare X-linked recessive pediatric disease caused by mutations of the copper transporter ATP7A encoded by the ATP7A gene. Patients with Menkes disease are born with the inability to absorb dietary copper and subsequently have impaired copper transport across the blood-brain barrier, and, until now, there has been no approved treatment in the United States. ZYCUBO� is a subcutaneous injectable formulation of copper histidinate that restores copper homeostasis and maintains copper levels in patients with Menkes disease.Powered by Capital Market - Live News

Bioeq AG (Bioeq), a Swiss biopharmaceutical company, and Zydus Lifesciences (Zydus), an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO�, an interchangeable biosimilar of Lucentis� (Ranibizumab) for the U.S. market. The Biologics License Application (BLA) for NUFYMCO� has been approved by U.S. Food and Drug Administration (USFDA) on December 18, 2025. This transaction marks an expansion of Zydus` U.S. biosimilar business, following its recent partnership with Formycon AG for a biosimilar of Keytruda� (Pembrolizumab).Under the terms of this agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the commercialisation of NUFYMCO� in the U.S. market.  Powered by Capital Market - Live News